Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7099252 | 0.76 | CHRNB2 (0.45) | CHRNB2CHRNA4LMNATDP1 | |
| SCHEMBL23934132 | 0.74 | CHRNB2 (0.44) | CHRNB2CHRNA4LMNATDP1CNR1 | |
| SCHEMBL29583666 | 0.73 | LMNA (0.50) | CHRNB2CHRNA4LMNATDP1 | |
| SCHEMBL2732089 | 0.73 | LMNA (0.50) | CHRNB2CHRNA4LMNATDP1 | |
| SCHEMBL27983764 | 0.71 | CHRNB2 (0.50) | CHRNB2CHRNA4LMNATDP1 | |
| SCHEMBL12549630 | 0.70 | CHRNB2 (0.49) | CHRNB2CHRNA4LMNATDP1CCNC | |
| SCHEMBL10915953 | 0.70 | CHRNB2 (0.49) | CHRNB2CHRNA4LMNATDP1CCNC | |
| SCHEMBL10672805 | 0.69 | CHRNB2 (0.45) | CHRNB2CHRNA4LMNATDP1CCNC | |
| SCHEMBL23934127 | 0.69 | CNR1 (0.45) | CHRNB2CHRNA4LMNATDP1CNR1 | |
| SCHEMBL7574405 | 0.69 | CHRNB2 (0.39) | CHRNB2CHRNA4LMNATDP1CCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6627648-B1 | Relevant nicotinic receptor subtypes to any significant degree. central nervous system disorders, are treated by administering to a patient in need thereof amine derivatives | TARGACEPT, INC. | 2003-09-30 | — | — | US | disclosed |
| US-6441006-B2 | NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-08-27 | — | — | US | disclosed |
| EP-1185513-A2 | ARYL SUBSTITUTED ALKYLAMINES CAPABLE OF ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| US-20010031771-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. | 2001-10-18 | — | — | US | disclosed |
| US-20010014691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. | 2001-08-16 | — | — | US | disclosed |
| WO-2000071520-A2 | ARYL SUBSTITUTED ALKYLAMINES CAPABLE OF ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031771-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | PNMT, TPMT, HTR7 | CHRNB2 98/4885CHRNA4 32/4885LMNA 1788/4885 |
| US-20010014691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | PNMT, HNMT, CHRM3 | CHRNB2 32/4885CHRNA4 34/4885LMNA 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.